22nd Century Group (XXII) Falls Following FDA Feedback on Very Low Nicotine MRTPA Filings
Tweet Send to a Friend
22nd Century Group (NYSE: XXII) is down 9% in early trade after the company announced that the FDA has provided ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
